Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden
文献类型：期刊论文
| 作者 | Wang, Rong1,2; Yang, Yuchen3; Ye, Wei-Wu1,2; Xiang, Jianxing3; Chen, Songan3; Zou, Wei-Bin1,2; Wang, Xiao-Jia1,2; Chen, Tianhui2,4; Cao, Wen-Ming1,2 |
| 刊名 | FRONTIERS IN ONCOLOGY
 |
| 出版日期 | 2021-02-09 |
| 卷号 | 10 |
| 关键词 | breast cancer immunotherapy biomarker TMB NGS molecular monitoring |
| ISSN号 | 2234-943X |
| DOI | 10.3389/fonc.2020.588080 |
| 通讯作者 | Cao, Wen-Ming(caowm@zjcc.org.cn) |
| 英文摘要 | Endocrine treatment plus CDK4/6 inhibitors have become standard of care for estrogen receptor positive (ER+) breast cancer. Although immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in a variety of cancer types, only limited success has been achieved for metastatic breast cancer (mBC) patients, especially the ER+ subtype, which usually exhibit lower tumor mutation burden (TMB) compared with other subtypes and therefore perceived as immunologically quiescent. Here we present a case of an ER+/HER2- but TMB-high mBC patient who had significant response to combination therapy with anti-PD-1 antibody camrelizumab and vinorelbine and obtained partial response (PR) with a progression-free survival (PFS) of 5 months after failure of multiple lines of therapy. Our case indicates that TMB may serve as a potential biomarker in immunotherapy selection for normally immunologically "cold" tumors such as ER+ mBC, also molecular monitoring during the whole treatment course plays an important role in patient management. |
| 资助项目 | Natural Science Foundation of Zhejiang Province, China[LY17H160038] ; Key Research-Development Program of Zhejiang Province[2020C04012] ; Key Research-Development Program of Zhejiang Province[2019C04001] ; Key Research-Development Program of Zhejiang Province[2017C03013] ; Health Bureau of Zhejiang Province, China[2017RC014] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000620353700001 |
| 出版者 | FRONTIERS MEDIA SA |
| 资助机构 | Natural Science Foundation of Zhejiang Province, China ; Key Research-Development Program of Zhejiang Province ; Health Bureau of Zhejiang Province, China |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/120640]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Cao, Wen-Ming |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Breast Med Oncol, Canc Hosp, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China 3.Burning Rock Biotech, Guangzhou, Peoples R China 4.Univ Chinese Acad Sci, Dept Canc Prevent, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Rong,Yang, Yuchen,Ye, Wei-Wu,et al. Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden[J]. FRONTIERS IN ONCOLOGY,2021,10. |
| APA | Wang, Rong.,Yang, Yuchen.,Ye, Wei-Wu.,Xiang, Jianxing.,Chen, Songan.,...&Cao, Wen-Ming.(2021).Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden.FRONTIERS IN ONCOLOGY,10. |
| MLA | Wang, Rong,et al."Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden".FRONTIERS IN ONCOLOGY 10(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。